×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Malignant Lymphoma Market Trends

ID: MRFR/Pharma/1329-HCR
85 Pages
Rahul Gotadki
October 2025

Malignant Lymphoma Market Research Report Information, by types (Hodgkin lymphoma and Non Hodgkin lymphoma), by treatment (chemotherapy, radiation therapy, immunotherapy, stem cell therapy and others) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Malignant Lymphoma Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Malignant Lymphoma Market

The market for malignant lymphoma treatment is encountering expanded demand, essentially determined by a developing rate of the infection universally. Factors like maturing populations, environmental factors, and further developed diagnostic capabilities contribute to the rising number of analyzed cases, necessitating effective and different treatment options. Immunotherapy is revolutionizing the scene of malignant lymphoma treatment. Checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and other immunotherapeutic methodologies are showing momentous outcome in certain lymphoma subtypes, giving patients new and targeted treatment options. Pushes in precision medication are molding treatment strategies for malignant lymphoma. Sub-atomic profiling and genetic testing take into consideration a more customized approach, identifying explicit genetic markers and sub-atomic characteristics of the lymphoma to modify treatment plans for individual patients. Pharmaceutical organizations are actively participated in the development of targeted therapies for malignant lymphoma. Targeted agents, for example, monoclonal antibodies and little particle inhibitors, expect to selectively attack cancer cells while limiting harm to healthy tissues, offering more effective and less toxic treatment options. The trend of consolidating different treatment modalities is acquiring noticeable quality in malignant lymphoma treatment. Combinatorial methodologies, which might incorporate chemotherapy, immunotherapy, and targeted therapies, are being investigated to upgrade treatment adequacy, reverse resistance, and work on generally patient outcomes. CAR T-cell therapy is arising as a transformative treatment for certain types of malignant lymphomas. This innovative methodology includes changing a patient's own T cells to target and destroy cancer cells, showing significant achievement, particularly in relapsed or refractory cases. Diagnostic imaging technologies are progressing, supporting early detection and accurate staging of malignant lymphomas. Positron emission tomography-computed tomography (PET-CT) filters and other high level imaging modalities contribute to exact determination, empowering clinicians to tailor treatment plans in view of disease characteristics.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

How does the outlook of the global malignant lymphoma market look like?

The outlook of the global malignant lymphoma market looks very promising.

What are the major tailwinds pushing the growth of the global malignant lymphoma market?

Increased government funding for the drug development and increment in the global economy that is widening the access to quality care are the major tailwinds pushing the growth of the global malignant lymphoma market.

Which region holds the largest share in the global malignant lymphoma market?

North America holds the largest share in the global malignant lymphoma market, followed by Europe and the Asia Pacific, respectively.

Who are the top players in the global malignant lymphoma market?

Abiogen Pharma S.p.A., Abbott Laboratories, Genmab, Actelion Pharmaceuticals, Allos Therapeutics, Aeterna Zentaris, Inc., Novartis, Astellas Pharma, Seattle Genetics Johnson & Johnson, Celgene Corporation, Bristol-Myers Squibb Company, Roche, Merck & Co. Inc., Eli Lilly and Company, Inovio Pharmaceuticals, and Onyx Pharmaceuticals, are some of the major players operating in the malignant lymphoma market.

What are the key growth strategies of malignant lymphoma industry players?

Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global malignant lymphoma market adopt to gain a larger competitive advantage.

Market Summary

As per Market Research Future Analysis, the malignant lymphoma market is projected to reach USD 8,365.4 Million by 2030, growing at a CAGR of 6.7% from 2022 to 2030. Lymphomas, prevalent forms of blood cancer, primarily affect men and are characterized by swollen glands. The market is driven by increasing clinical trials, rising cancer prevalence, and advancements in treatment options. However, high treatment costs and stringent regulations pose challenges. The COVID-19 pandemic has negatively impacted treatment accessibility, but recovery is anticipated as restrictions ease.

Key Market Trends & Highlights

Key trends influencing the malignant lymphoma market include advancements in treatment and increasing prevalence.

  • Market expected to reach USD 8,365.4 Million by 2030 at a CAGR of 6.7%; Non-Hodgkin lymphoma predicted to dominate market share due to higher case prevalence; Immunotherapy segment holds significant market share, driven by products like Yescarta; North America accounts for the largest market share due to high prevalence and treatment awareness.

Market Size & Forecast

Market Size USD 8,365.4 Million by 2030
CAGR 6.7% from 2022 to 2030
Largest Regional Market Share North America.

Major Players

<p>Key players include Amgen, Spectrum Pharmaceuticals, Abbott Laboratories, Bristol-Myers Squibb, and Eli Lilly.</p>

Market Trends

Drivers:

Increasing the clinical trials for developing the new drug candidates for various forms of lymphomas specifically for the harder treatment forms is anticipated to accelerate the growth of the market. The growing involvement of major companies in research and development leads to strong pipeline candidates that may propel market growth in the forecast period.

The rising prevalence of all forms of cancers including other types of blood cancers is one of the key driving factors of the market growth. The disease Lymphoma consists of a few blood cancer cases and there is a rise in demand for advanced products for the treatment. The essential thing was there are no clinical signs for the disease till it is in later stages. At this later stage, a more aggressive form of treatment is required for improved treatment outcomes. This factor is predicted to spur global market growth in the coming years.

Restraint:

Expensive treatment, complications related to drugs, low treatment options, and the presence of stringent regulatory guidelines are hampering the market growth.

Opportunities:

A rise in the number of improved diagnostic techniques and FDA approvals for therapy drugs may create an opportunity for key players to raise the market growth.

Challenges:

Due to the lower lymphoma treatment rates in emerging countries, the cost of the therapies becomes expensive which is reducing the number of individuals undergoing this treatment and most of the patients are not able to afford treatments like immunotherapies. Because the cost of these treatments is not affordable and accessible to poor people.

Study Objectives

To provide detailed information about the market structure along with many forecast segments and subsegments for the next 7 years.

To provide the factors that are impacting the growth of the market value.

 To evaluate the malignant lymphoma market industry analysis based on porter’s five force analysis, factors-price analysis, etc.

To provide previous and forecast revenue segments and sub-segments of the market revenue for the four main geographies.

To offer the country-level analysis of the current market size and future prospective. 

To provide country-level analysis of the global market industry growth by region, type, treatment, and application.

To provide a strategic profile of the prominent key competitors in the market, analyze their core competencies, and draw a global market growth landscape.

To track and analyze new product developments, joint ventures, strategic alliances, and global market research.

Malignant Lymphoma Market Market Drivers

Rising Incidence of Malignant Lymphoma

The Global Malignant Lymphoma Market Industry is experiencing growth due to the increasing incidence of malignant lymphoma worldwide. According to health statistics, the prevalence of lymphoma cases has been on the rise, with an estimated 4.37 USD Billion market value in 2024. This surge is attributed to factors such as improved diagnostic techniques and heightened awareness among healthcare professionals and patients. As more individuals are diagnosed, the demand for effective treatment options escalates, thereby driving market expansion. The growing population and aging demographics further contribute to the increase in lymphoma cases, indicating a sustained need for innovative therapies in the Global Malignant Lymphoma Market Industry.

Market Segment Insights

Malignant Lymphoma Market Treatment Insights

<p>Based on the treatment, the malignant lymphoma market is partitioned into various segments like radiation therapy, chemotherapy, immunotherapy, stem cell therapy, and others. Among them, the immunotherapy segment is holding a significant share due to the higher revenue realization of these drugs. Immunotherapies named Yescarta, a dominant product in this treatment is introduced by Kite Pharma, Inc.</p>

Get more detailed insights about Malignant Lymphoma Market Research Report- Global Forecast To 2035

Regional Insights

Key Companies in the Malignant Lymphoma Market market include

Industry Developments

In May 2021, the popular enterpriser PerkinElmer, Inc is planning to acquire the Immunodiagnostic Systems Holdings PLC with an investment of nearly $155 million for expanding their overall diagnostics business.

In March 2020, one of the well-known companies Kura Oncology conducted a clinical trial for a pipeline candidate named tipifarnib which is used for the disease indication of peripheral T-cell lymphoma. Present, the clinical trial is in Phase-II and it received the fast track designation from the FDA.

In February 2021, the famous enterpriser Bristol Myers Squibb announced that their company received approval from the U.S Food and Drug Administration (FDA) for cancer immunotherapy as a treatment for adults who are having certain types of non-Hodgkin lymphoma.

Future Outlook

Malignant Lymphoma Market Future Outlook

<p>The Global Malignant Lymphoma Market is projected to grow at a 9.27% CAGR from 2024 to 2035, driven by advancements in targeted therapies and increasing patient awareness.</p>

New opportunities lie in:

  • <p>Invest in research for novel immunotherapies to enhance treatment efficacy. Develop digital health solutions for patient monitoring and engagement. Expand access to clinical trials in emerging markets to capture new patient demographics.</p>

<p>By 2035, the market is expected to demonstrate robust growth, reflecting advancements in treatment and increased global awareness.</p>

Market Segmentation

Malignant Lymphoma Market Competitive Landscape

  • Abbott Laboratories
  • Actelion Pharmaceuticals
  • Allos Therapeutics
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Genmab
  • Roche
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Onyx Pharmaceuticals
  • Seattle Genetics
  • ABIOGEN PHARMA S.P.A
  • Aeterna Zentaris
  • Inc
  • Astellas Pharma
  • Eli Lilly and Company
  • Merck & Co. Inc
  • Novartis

Report Scope

Attribute/MetricDetails
  Market Size  8,365.4 Million
  CAGR (2022-2030)  6.7%
  Base Year  2021
  Forecast Period  2022-2030
  Historical Data  2020
  Forecast Units  Value (USD Million)
  Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered Types and treatment
  Geographies Covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors Abbott Laboratories, ABIOGEN PHARMA S.p.A., Actelion Pharmaceuticals, Aeterna Zentaris, Inc., Allos Therapeutics, Astellas Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Genmab, Inovio Pharmaceuticals, Johnson & Johnson, and Merck & Co. Inc., Novartis, Onyx Pharmaceuticals, Roche, Seattle Genetics
  Key Market OpportunitiesTechnological advancement, macro economical and governing factors
  Key Market DriversJoint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments

FAQs

How does the outlook of the global malignant lymphoma market look like?

The outlook of the global malignant lymphoma market looks very promising.

What are the major tailwinds pushing the growth of the global malignant lymphoma market?

Increased government funding for the drug development and increment in the global economy that is widening the access to quality care are the major tailwinds pushing the growth of the global malignant lymphoma market.

Which region holds the largest share in the global malignant lymphoma market?

North America holds the largest share in the global malignant lymphoma market, followed by Europe and the Asia Pacific, respectively.

Who are the top players in the global malignant lymphoma market?

Abiogen Pharma S.p.A., Abbott Laboratories, Genmab, Actelion Pharmaceuticals, Allos Therapeutics, Aeterna Zentaris, Inc., Novartis, Astellas Pharma, Seattle Genetics Johnson &amp; Johnson, Celgene Corporation, Bristol-Myers Squibb Company, Roche, Merck &amp; Co. Inc., Eli Lilly and Company, Inovio Pharmaceuticals, and Onyx Pharmaceuticals, are some of the major players operating in the malignant lymphoma market.

What are the key growth strategies of malignant lymphoma industry players?

Strategic initiatives such as mergers &amp; acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global malignant lymphoma market adopt to gain a larger competitive advantage.

  1. INTRODUCTION
    1. DEFINITION
    2. SCOPE OF STUDY
      1. RESEARCH OBJECTIVE
      2. ASSUMPTIONS & LIMITATIONS
    3. MARKET STRUCTURE:
  2. RESEARCH METHODOLOGY
    1. RESEARCH PROCESS:
    2. PRIMARY RESEARCH
    3. SECONDARY RESEARCH:
  3. MARKET DYNAMICS
    1. DRIVERS
    2. RESTRAINTS
    3. OPPORTUNITIES
    4. MACROECONOMIC INDICATORS
  4. MARKET FACTOR ANALYSIS
    1. PORTERS FIVE FORCES MODEL
    2. BARGAINING POWER OF SUPPLIERS
    3. BARGAINING POWER OF BUYERS
    4. THREAT OF NEW ENTRANTS
    5. THREAT OF SUBSTITUTES
    6. INTENSITY OF RIVALRY
  5. GLOBAL MALIGNANT LYMPHOMA MARKET, BY TYPE
    1. HODGKIN LYMPHOMA
    2. NON-HODGKIN LYMPHOMA
  6. GLOBAL MALIGNANT LYMPHOMA MARKET, BY OCCURANCE
    1. LYMPH NODES
    2. BONE MARROW
    3. SPLEEN
    4. BLOOD
    5. OTHER ORGANS
  7. GLOBAL MALIGNANT LYMPHOMA MARKET, BY DIAGNOSTIC TESTS
    1. IMMUNOPHENOTYPING
    2. FLUORESCENCE IN SITU HYBRIDIZATION TESTING
    3. FLOW CYTOMETER
  8. GLOBAL MALIGNANT LYMPHOMA MARKET
    1. CHEMOTHERAPY
    2. RADIATION THERAPY
    3. IMMUNOTHERAPY
    4. STEM CELL THERAPY
    5. OTHERS
  9. GLOBAL MALIGNANT LYMPHOMA MARKET, BY REGION
    1. INTRODUCTION
    2. NORTH AMERICA
      1. US
      2. CANADA
    3. EUROPE
      1. WESTERN EUROPE
      2. EASTERN EUROPE
    4. ASIA
      1. JAPAN
      2. CHINA
      3. INDIA
      4. AUSTRALIA
      5. REPUBLIC OF KOREA
      6. REST OF ASIA-PACIFIC
    5. MIDDLE EAST & AFRICA
      1. UNITED ARAB EMIRATES
      2. SAUDI ARABIA
      3. OMAN
      4. KUWAIT
      5. QATAR
      6. REST OF MIDDLE EAST & AFRICA
  10. COMPETITIVE LANDSCAPE
    1. MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
      1. STRATEGIC PARTNERSHIP
      2. MERGER & ACQUISITION
  11. COMPANY PROFILE
    1. ABBOTT LABORATORIES
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. FINANCIALS
      4. KEY DEVELOPMENTS
    2. ABIOGEN PHARMA
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. FINANCIALS
      4. KEY DEVELOPMENTS
    3. ACTELION PHARMACEUTICALS
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. FINANCIALS
      4. STRATEGY
      5. KEY DEVELOPMENT
    4. ALLOS THERAPEUTICS
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. FINANCIALS
      4. KEY DEVELOPMENTS
    5. BRISTOL-MYERS SQUIBB COMPANY
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. FINANCIALS
      4. KEY DEVELOPMENTS
    6. OTHERS

Malignant Lymphoma Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne

Founder
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓